On December 4, 2025, ENDRA Life Sciences (NASDAQ: NDRA) revealed promising data from its 2025 feasibility study of the TAEUS Liver device. The study demonstrated that the device’s thermo-acoustic fat fraction measurements align closely with the MRI-PDFF gold standard at critical liver fat fraction thresholds. Despite these findings, ENDRA’s stock declined 10%, reflecting investor caution about regulatory timelines and commercial prospects. The device is intended to offer a substantially less expensive option to current MRI imaging in metabolic liver disease management and drug development.

Feasibility Study Validates High Accuracy at Clinical Thresholds

The study assessed the TAEUS device’s performance in detecting liver fat fractions at two key ranges: 12-17% and 20-22%, which correspond to clinical categories of mild, moderate, and severe steatotic liver disease. Within the 12-17% bracket, the device achieved a positive predictive value (PPV) of 100%, negative predictive value (NPV) of 94%, and overall accuracy of 95%. For the 20-22% liver fat fraction range, the device recorded a PPV of 90%, NPV of 94%, and accuracy of 94%. These results affirm the TAEUS device’s reliability in identifying patient stratification across liver disease severities.

CEO Alexander Tokman underscored the economic significance of the device, stating, “Drug developers and payors need to know if a patient is above or below the specific thresholds that trigger costly therapies, reimbursement of those therapies or trial enrollment.” Currently, an MRI-PDFF procedure can exceed $2,500 in cost, while ENDRA anticipates pricing the TAEUS device at under $200. This price difference could revolutionize liver fat quantification by lowering imaging expenses in clinical trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity.

Ongoing Validation and Regulatory Engagement

Following the initial study, ENDRA has initiated a second feasibility trial in London, Ontario, to broaden validation beyond the original single-center environment. This study is slated for completion in the coming months. The company also plans to consult with the U.S. Food and Drug Administration (FDA) in 2026 to discuss the design of pivotal studies required for a future De Novo regulatory submission.

The stock’s 10% decline after the announcement suggests investors are carefully weighing the timing and risks associated with bringing this novel device to market. Nonetheless, if ENDRA successfully navigates regulatory hurdles and commercialization, the TAEUS Liver device could significantly reduce diagnostic costs in the growing MASLD and obesity treatment markets.

ENDRA Life Sciences Stock: Market Outlook

ENDRA Life Sciences’ recent feasibility study details a technology that performs with impressive accuracy at important clinical liver fat thresholds while offering a steep cost advantage over current MRI methods. The ongoing second study and planned FDA discussions will be crucial for advancing the device toward commercial viability. Investors should monitor forthcoming clinical data updates and regulatory milestones closely, as these factors will shape ENDRA’s stock trajectory and its role in liver disease diagnostics.